(PGNY) Progyny - Overview
Stock: Fertility Benefits, Pharmacy Solution, Family Building
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 47.0% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha | -14.12 |
| Character TTM | |
|---|---|
| Beta | 0.575 |
| Beta Downside | 0.288 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.14% |
| CAGR/Max DD | -0.17 |
Description: PGNY Progyny January 14, 2026
Progyny, Inc. (NASDAQ:PGNY) is a U.S.-based benefits management firm that specializes in fertility, family-building, and women’s health solutions for employers. Its core offering combines a differentiated benefits plan design-including a “smart cycle” treatment bundle-with concierge-style member support and a curated network of fertility specialists. The company also delivers an integrated pharmacy benefit (Progyny Rx) to cover treatment medications and provides care-management services, as well as a reimbursement-based assistance program covering adoption, surrogacy, doula services, and travel costs when medical care is out-of-area.
Key recent metrics suggest strong market traction: FY 2023 revenue reached approximately $1.3 billion, up roughly 30% year-over-year, while the subscriber base grew about 20% as more employers add fertility benefits to attract and retain talent. The fertility benefits market is expanding at a ~7% CAGR, driven by rising demand for family-building support among younger workforces and increasing employer willingness to fund high-cost treatments. A sector-wide driver is the broader shift toward comprehensive employee wellness packages, which has accelerated adoption of integrated solutions like Progyny’s.
For a deeper quantitative view, you might explore ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 56.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.24 > 0.02 and ΔFCF/TA -0.37 > 1.0 |
| NWC/Revenue: 32.44% < 20% (prev 29.67%; Δ 2.77% < -1%) |
| CFO/TA 0.26 > 3% & CFO 205.1m > Net Income 56.6m |
| Net Debt (-109.3m) to EBITDA (95.4m): -1.14 < 3 |
| Current Ratio: 2.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.2m) vs 12m ago -3.83% < -2% |
| Gross Margin: 22.94% > 18% (prev 0.22%; Δ 2272 % > 0.5%) |
| Asset Turnover: 174.4% > 50% (prev 172.5%; Δ 1.82% > 0%) |
| Interest Coverage Ratio: -21.47 > 6 (EBITDA TTM 95.4m / Interest Expense TTM -4.24m) |
Altman Z'' 5.87
| A: 0.52 (Total Current Assets 622.0m - Total Current Liabilities 210.5m) / Total Assets 795.2m |
| B: 0.24 (Retained Earnings 190.3m / Total Assets 795.2m) |
| C: 0.13 (EBIT TTM 91.0m / Avg Total Assets 727.6m) |
| D: 0.81 (Book Value of Equity 190.8m / Total Liabilities 235.2m) |
| Altman-Z'' Score: 5.87 = AAA |
Beneish M -3.22
| DSRI: 0.81 (Receivables 252.5m/280.7m, Revenue 1.27b/1.14b) |
| GMI: 0.94 (GM 22.94% / 21.68%) |
| AQI: 1.21 (AQ_t 0.15 / AQ_t-1 0.13) |
| SGI: 1.11 (Revenue 1.27b / 1.14b) |
| TATA: -0.19 (NI 56.6m - CFO 205.1m) / TA 795.2m) |
| Beneish M-Score: -3.22 (Cap -4..+1) = AA |
What is the price of PGNY shares?
Over the past week, the price has changed by -8.04%, over one month by -17.70%, over three months by +21.88% and over the past year by +0.55%.
Is PGNY a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PGNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.9 | 40.8% |
| Analysts Target Price | 30.9 | 40.8% |
| ValueRay Target Price | 20.2 | -7.9% |
PGNY Fundamental Data Overview February 03, 2026
P/E Forward = 11.8765
P/S = 1.622
P/B = 3.6747
Revenue TTM = 1.27b USD
EBIT TTM = 91.0m USD
EBITDA TTM = 95.4m USD
Long Term Debt = 24.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.86m USD (from shortTermDebt, last fiscal year)
Debt = 24.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -109.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.74b USD (2.06b + Debt 24.7m - CCE 345.2m)
Interest Coverage Ratio = -21.47 (Ebit TTM 91.0m / Interest Expense TTM -4.24m)
EV/FCF = 9.13x (Enterprise Value 1.74b / FCF TTM 190.4m)
FCF Yield = 10.96% (FCF TTM 190.4m / Enterprise Value 1.74b)
FCF Margin = 15.01% (FCF TTM 190.4m / Revenue TTM 1.27b)
Net Margin = 4.46% (Net Income TTM 56.6m / Revenue TTM 1.27b)
Gross Margin = 22.94% ((Revenue TTM 1.27b - Cost of Revenue TTM 977.7m) / Revenue TTM)
Gross Margin QoQ = 23.24% (prev 23.72%)
Tobins Q-Ratio = 2.18 (Enterprise Value 1.74b / Total Assets 795.2m)
Interest Expense / Debt = 2.85% (Interest Expense 706.0k / Debt 24.7m)
Taxrate = 42.15% (10.1m / 24.0m)
NOPAT = 52.6m (EBIT 91.0m * (1 - 42.15%))
Current Ratio = 2.96 (Total Current Assets 622.0m / Total Current Liabilities 210.5m)
Debt / Equity = 0.04 (Debt 24.7m / totalStockholderEquity, last quarter 560.0m)
Debt / EBITDA = -1.14 (Net Debt -109.3m / EBITDA 95.4m)
Debt / FCF = -0.57 (Net Debt -109.3m / FCF TTM 190.4m)
Total Stockholder Equity = 491.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.77% (Net Income 56.6m / Total Assets 795.2m)
RoE = 11.52% (Net Income TTM 56.6m / Total Stockholder Equity 491.1m)
RoCE = 17.64% (EBIT 91.0m / Capital Employed (Equity 491.1m + L.T.Debt 24.7m))
RoIC = 10.72% (NOPAT 52.6m / Invested Capital 491.1m)
WACC = 7.95% (E(2.06b)/V(2.08b) * Re(8.03%) + D(24.7m)/V(2.08b) * Rd(2.85%) * (1-Tc(0.42)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.37%
[DCF Debug] Terminal Value 81.41% ; FCFF base≈178.4m ; Y1≈220.1m ; Y5≈374.8m
Fair Price DCF = 75.41 (EV 6.39b - Net Debt -109.3m = Equity 6.50b / Shares 86.2m; r=7.95% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 80.71 | EPS CAGR: 34.04% | SUE: 2.62 | # QB: 2
Revenue Correlation: 88.59 | Revenue CAGR: 27.08% | SUE: 1.14 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.50 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=1.97 | Chg30d=+0.008 | Revisions Net=+2 | Growth EPS=+8.3% | Growth Revenue=+9.4%